je.st
news
Tag: merck
PolyOne, Merck partner to create 3D effects
2016-10-16 02:28:23| Canadian Plastics Headlines
Material supplier PolyOne Corporation is partnering with German multinational chemical, pharmaceutical and life sciences company Merck KGaA to develop smooth, molded plastics that appear to have three-dimensional surfaces. The Merck technology, called in-mold 3-D (IM3D), creates the effect with the… The post PolyOne, Merck partner to create 3D effects appeared first on Canadian Plastics.
Tags: create
partner
effects
merck
Merck Launches Biosimilars Clarified, a New Online Educational Resource about Biosimilar Medicines for Patients and the Healthcare Community
2016-10-14 14:30:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the launch of Biosimilars Clarified (www.merckclarifiesbiosimilars.com), a new educational website for patients, caregivers and the healthcare community that is designed to provide clear, concise and straightforward information about biosimilar medicines. Language: English Contact: MerckRobert Consalvo, 908-236-1127 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
online
community
resource
Merck KGaA, Darmstadt, Germany, Defines Blue-Glow Purple as the Effect Color of 2017
2016-10-11 19:00:00| Coatings World Breaking News
Tags: germany
color
effect
purple
Merck Announces Longer-Term Follow-Up of Overall Survival Data for KEYTRUDA (pembrolizumab) in Patients with Advanced Melanoma from KEYNOTE-002 Presented at ESMO 2016 Congress
2016-10-08 14:45:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Data Comparing KEYTRUDA to Chemotherapy Shows Continued Benefit with Follow-Up Beyond 2.5 Years in Patients with Ipilimumab-Refractory Advanced Melanoma KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced findings from the final overall survival (OS) analysis from the KEYNOTE-002 study investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, compared to investigator-choice chemotherapy with a crossover to KEYTRUDA design, in patients with ipilimumab-refractory advanced melanoma. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
advanced
presented
patients
Merck Animal Health Announces USDA Approval of Innovative Canine Flu Bivalent Vaccine
2016-10-07 22:05:00| Merck.com - Corporate News
Dateline City: MADISON, N.J. First Vaccine to Offer Protection Against Both Strains of Canine Influenza MADISON, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, today announced that the U.S. Department of Agriculture has approved a license for Nobivac Canine Flu Bivalent vaccine the first vaccine to aid in the control of disease associated with both canine influenza virus (CIV) H3N2 and canine influenza virus H3N8. Language: English Contact: MerckMedia:Kelly Goss, 913-558-6452 kelly.goss@merck.com orPamela Eisele, 267-305-3558 pamela.eisele@merck.com orInvestor Relations:Amy Klug, 908-740-1898 amy.klug@merck.com Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: health
animal
approval
innovative
Sites : [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] next »